Breast cancer is the most common malignant tumor among Chinese women. Its diagnosis and treatment deeply perplex women of all ages. Surgery, chemotherapy, targeted therapy, endocrine therapy... Every step of treatment makes people suffer.
Accompanied by treatment, it is often high medical costs. In recent years, more and more drugs for breast cancer have entered the medical insurance catalogue, which is undoubtedly a great hope for many families. Today, I will take you to master the reimbursement of drugs for the treatment of breast cancer at all stages
About medical insurance reimbursement - what you need to know
Usually I always hear people say that medical insurance reimbursement, how much can it be reimbursed? Is it really all reimbursable?
In fact, there are certain rules for medical insurance reimbursement. Different types of drugs have different reimbursement proportions. In the national medical insurance standard classification, drugs are divided into three categories: A, B and C, and the reimbursement of each category of drugs is quite different.
1. Category A: all of them are included in the scope of medical insurance reimbursement, with 100% reimbursement; It is mainly aimed at some drugs that are necessary for clinical treatment, have good curative effect, and have low prices among similar drugs;
2. Category B: partially reimbursed, and a part of the drug cost needs to be paid by oneself; Generally, it is clinically selectable, with good curative effect, and the price of similar drugs is higher than that of class a drugs;
3. Class C: not reimbursed, all at their own expense, that is, not within the scope of medical insurance; Generally imported antineoplastic drugs, new drugs, etc;
And a, B and C are not completely fixed. In the annual medical insurance negotiation, there will be changes in the reimbursement type of some drugs, or new drugs will be included in the scope of medical insurance reimbursement.
For the treatment of breast cancer, according to the main treatment schemes mentioned in the "guidelines for diagnosis and treatment of breast cancer (2022 Edition)" prepared by the Chinese expert group, there are mainly three categories: neoadjuvant chemotherapy, advanced chemotherapy and targeted drug therapy.
Adjuvant chemotherapy
Among the neoadjuvant chemotherapy regimens for breast cancer, TAC regimen is commonly used at present, that is, docetaxel + doxorubicin + cyclophosphamide. In addition to the above drugs, epirubicin and fluorouracil are also involved in other neoadjuvant chemotherapy schemes.
The reimbursement types of these drugs are as follows (the prices are for reference only, and the production prices of different manufacturers vary greatly, subject to the actual commodity name price):
Late chemotherapy
In the advanced chemotherapy of breast cancer, there are mainly two schemes: single drug chemotherapy and combined chemotherapy.
In single drug chemotherapy, paclitaxel, capecitabine, gemcitabine and other drugs are generally recommended to be preferred in clinic;
Among the combined chemotherapy schemes, TX (docetaxel + capecitabine) and GC (gemcitabine + carboplatin) are commonly used. Other used combined chemotherapy regimens include CaF (cyclophosphamide + doxorubicin + 5-fluorouracil), CMF (cyclophosphamide + methotrexate + 5-fluorouracil), etc.
The following are the types of drug reimbursement mentioned (the price is for reference only, subject to the actual):
Targeted drugs
In addition to traditional chemotherapy, with the continuous development of medical treatment technology to accurate and individualized treatment, targeted drugs have also played a huge advantage in the treatment of breast cancer, and the curative effect is significant, mainly including trastuzumab, patuzumab, pyrrolidine and other drugs.
The following are the types of drug reimbursement mentioned (the price is for reference only, subject to the actual):
The above is some reimbursement knowledge of commonly used drugs for the treatment of breast cancer. I hope it can help you.
The medical insurance negotiation in 2022 is also about to begin. It is believed that more therapeutic drugs will be included in the scope of medical insurance, bringing the gospel of treatment to the majority of breast cancer patients.
Source link：
https://mp.weixin.qq.com/s/KRohewXogQtQ7mkdE63d4Q
